The Optobionics Corp. Pilot Clinical Study Shows Promising Vision Improvement For Retinitis Pigmentosa Patients  
10/25/2006 10:16:04 AM

NAPERVILLE, Ill.--(BUSINESS WIRE)--Optobionics Corporation, a developer of innovative medical devices for the treatment of vision loss due to degenerative retinal diseases, today provided an update on the interim results from its multi-center, pilot clinical study of the Artificial Silicon Retina (ASRĀ®) device. Results from the 20 patients treated with the ASR device show measurable vision improvement in a significant number of Retinitis Pigmentosa patients. These patients currently have no treatment options available and face deteriorating vision leading to blindness. Patients were enrolled in the study to assess safety and develop effective vision measures under an Investigational Device Exemption application approved by the U.S. Food and Drug Administration. The patients were followed for at least 12 months.